The latest Investing Matters Podcast episode with Inclusive Asset Management's Alexandra McGuigan has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.625
Bid: 3.50
Ask: 3.75
Change: 0.00 (0.00%)
Spread: 0.25 (7.143%)
Open: 3.625
High: 3.625
Low: 3.625
Prev. Close: 3.625
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ValiRx gets US patent protection for use of VAL201 peptide

Wed, 26th Jun 2019 10:53

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Wednesday that the US Patent and Trademark Office (USPTO) has allowed patent claims directed towards a method of preventing the worsening of symptoms of metastatic cancer, reducing the progression of metastatic cancer, or treating metastatic cancer - including prostate cancer - by administration of the 'VAL201' peptide.The AIM-traded firm explained that advanced prostate cancer was classified when disease spread beyond the prostate to other parts of the body.That spread was known as metastatic disease, and in prostate cancer the most common spread was to the bones and lymph nodes.The company said the main goals for treatment of advanced prostate cancer were symptom control, slowing the rate at which the cancer grows, as well as targeting the tumour.ValiRx claimed the VAL201 compound "selectively prevents" tumour growth, by specifically inhibiting the proliferation of tumour cells.It said its inhibitory effects on lymph node metastases had been demonstrated in the pre-clinical prostate cancer model.The compound was currently in a phase 1 and 2 study, primarily assessing safety and tolerability of VAL201 and its effect in the treatment of prostate cancer and other solid tumours.VAL201 had been well tolerated, the firm claimed, with signs of activity in advanced prostate cancer noted through biomarker and imaging techniques."With previously granted worldwide rights for the use of VAL201 in prostate cancer, we are very pleased that the USPTO has allowed claims for the use of VAL201 in the prevention and treatment of metastatic - including prostate - cancer," said ValiRx chief executive officer Dr Satu Vainikka."I believe that not only will the allowed claims complement our other intellectual property and provide the company with a more compelling package to offer when in discussions with big pharma, but I also believe that if we can reduce the symptoms and progression of metastases, as well as targeting the lesion, through the use of VAL201, we can improve prospects for patients."
More News
21 Mar 2024 11:22

ValiRx inks evaluation deal with Imperial College London for research

(Alliance News) - ValiRx PLC on Thursday said that it has signed an evaluation deal with Imperial College London to look at research on novel therapeutic candidates for cancer treatment.

Read more
19 Mar 2024 19:47

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
13 Feb 2024 14:45

ValiRx says requisition notice from shareholder group is invalid

(Alliance News) - ValiRx PLC on Tuesday said a requisition notice, which it received earlier in February, has been confirmed as invalid following legal advice.

Read more
12 Feb 2024 12:59

ValiRx inks deal with Dundee Drug Discovery Unit

(Sharecast News) - ValiRx announced the signing of a significant agreement with the University of Dundee and its Drug Discovery Unit (DDU) on Monday.

Read more
12 Feb 2024 11:42

IN BRIEF: ValiRx signs research sharing deal with Dundee University

ValiRx PLC - Nuneaton, England-based life sciences company focused on early-stage cancer therapeutics - Signs agreement with Dundee University's drug discovery unit to access research concerning novel therapeutic candidates. The agreement will be active for a period of five years, in which ValiRx may review research projects from the unit in areas aligned with the company's focus on cancer therapeutics.

Read more
9 Feb 2024 20:24

TRADING UPDATES: ValiRx receives shareholder request for board change

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
28 Dec 2023 15:56

UK shareholder meetings calendar - next 7 days

Friday 29 December 
Apollon Formularies PLCAGM
Eco Atlantic Oil & Gas LtdAGM
Genedrive PLCAGM
Goldplat PLCAGM
Lansdowne Oil & Gas PLCGM re capital raise
Marula Mining PLCAGM
Microsaic Systems PLCGM re fundraise
Online Blockchain PLCAGM
Secure Property Development & Investment PLCAGM
SkinBioTherapeutics PLCAGM
Tetragon Financial Group LtdAGM
Woodbois LtdAGM
Zambeef Products PLCAGM
Monday 1 January 
no events scheduled 
Tuesday 2 January 
no events scheduled 
Wednesday 3 January 
Jubilee Metals Group PLCGM re equity raise
Thursday 4 January 
Rotala PLCGM re management buyout
Tintra PLCGM re cancellation, re-registering as private company
ValiRx PLCGM re operational review
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
19 Dec 2023 20:46

IN BRIEF: ValiRx raises GBP192,200, part of wider GBP1.8 million raise

ValiRx PLC - life science company based near Birmingham, England, which is focused on early-stage cancer therapeutics and women's health - Says 3.2 million new shares have been subscribed for at 6 pence per share via a retail offer, raising GBP192,244. Also issues 499,998 new shares via a subscription. In total, raises GBP1.8 million via placing, subscription and retail offer of 30.0 million new shares.

Read more
13 Dec 2023 21:14

TRADING UPDATES: Good Energy says ZapMap expands into mainland Europe

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
5 Dec 2023 15:08

ValiRx enters option deal with Ambrose Healthcare

(Sharecast News) - Cancer therapeutics-focussed life science company ValiRx announced on Tuesday that its subsidiary ValiSeek has entered into an exclusive option agreement with Ambrose Healthcare, a private UK-based pharmaceutical company.

Read more
5 Dec 2023 11:17

ValiRx says ValiSeek inks deal to licence VAL401 drug with Ambrose

(Alliance News) - ValiRx PLC on Tuesday said that ValiSeek Ltd it has entered a deal to licence VAL401 with Ambrose Healthcare Ltd, a private UK specialist pharmaceutical company.

Read more
5 Dec 2023 10:59

AIM WINNERS & LOSERS: tinyBuild warns on revenue; ValiRx rises

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
10 Nov 2023 11:49

ValiRx signs deal to evaluate StingRay Bio drug candidates

(Alliance News) - ValiRx PLC on Friday said it has signed a deal with StingRay Bio Ltd to investigate a series of drug candidates.

Read more
10 Nov 2023 10:32

ValiRx enters partnership with StingRay Bio

(Sharecast News) - Life science company ValiRx announced a new partnership with StingRay Bio on Friday, aiming to explore a promising lead series of drug candidates designed for oncology applications.

Read more
6 Oct 2023 11:35

ValiRx sees no reason for shares jump; notes TheoremRx mulls merger

(Alliance News) - ValiRx PLC on Friday said it had no unpublished information that was sensitive to its share price, as it rose significantly.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.